Bremer, S.C.B.; Bittner, G.; Elakad, O.; Dinter, H.; Gaedcke, J.; König, A.O.; Amanzada, A.; Ellenrieder, V.; Freiherr von Hammerstein-Equord, A.; Ströbel, P.;
et al. Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis. Cancers 2022, 14, 2828.
https://doi.org/10.3390/cancers14122828
AMA Style
Bremer SCB, Bittner G, Elakad O, Dinter H, Gaedcke J, König AO, Amanzada A, Ellenrieder V, Freiherr von Hammerstein-Equord A, Ströbel P,
et al. Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis. Cancers. 2022; 14(12):2828.
https://doi.org/10.3390/cancers14122828
Chicago/Turabian Style
Bremer, Sebastian C. B., Gabi Bittner, Omar Elakad, Helen Dinter, Jochen Gaedcke, Alexander O. König, Ahmad Amanzada, Volker Ellenrieder, Alexander Freiherr von Hammerstein-Equord, Philipp Ströbel,
and et al. 2022. "Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis" Cancers 14, no. 12: 2828.
https://doi.org/10.3390/cancers14122828
APA Style
Bremer, S. C. B., Bittner, G., Elakad, O., Dinter, H., Gaedcke, J., König, A. O., Amanzada, A., Ellenrieder, V., Freiherr von Hammerstein-Equord, A., Ströbel, P., & Bohnenberger, H.
(2022). Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis. Cancers, 14(12), 2828.
https://doi.org/10.3390/cancers14122828
